Kathryn D. Doyle

Kate Doyle is a patent attorney with extensive experience in patent prosecution with a focus on domestic and international patent filing and regulatory compliance.

• Advises clients regarding domestic and international strategies to maximize pharmaceutical patent life cycles post-issuance, including Hatch-Waxman, international working requirements, patent linkage, data exclusivity, and patent term extension
• Assists clients in a wide range of intellectual property matters, including patent portfolio management, patent application drafting, due diligence, patent validity and non-infringement analysis, and licensing
• Drafts and prosecutes patents in a variety of technical areas, such as pharmaceutical, nutraceutical, medical device, biotechnology, life science, food chemistry, and mechanical
• Possesses experience with trademark prosecution, as well as various corporate litigation matters such as party and witness depositions, negotiations, case evaluations, settlement conferences, and motion practice, including researching and preparing briefs and presenting oral arguments

Practice Areas

Industries

Representative Matters

• Prosecuted composition of matter and second generation patents in the United States and more than 70 foreign jurisdictions, relating to hepatitis C virus therapeutic, INCIVEK® (telaprevir)
• Provided global strategy analysis and advice, particularly relating to patent prosecution and patent term extension to pharmaceutical clients relating to efforts to maximize pharmaceutical patent life cycles in many foreign jurisdictions
• Assisted pharmaceutical clients in applying for or obtaining patent term extension in various foreign jurisdictions, including Australia, Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovenia, Spain, Sweden, Switzerland, and the United Kingdom
• Prepared and assisted in the preparation of several patent term extension applications for pharmaceutical products that received marketing approval in the United States
• Advised numerous life sciences clients regarding working requirements and compulsory licensing in various jurisdictions, such as Australia, Brazil, China, Israel, Japan, New Zealand, and European countries
• Prepared annual "working statements" for India and advised pharmaceutical clients regarding the affirmative duty to work the invention in India
• Counseled pharmaceutical clients regarding coordination of regulatory efforts and patent prosecution developments for therapeutic drug products in Canada
• Assisted in the preparation and filing of Patented Medicines (Notice of Compliance) Regulations Patent List for medicinal products in Canada, as well as preparation of Patented Medicine Prices Review Board Forms
• Participated in strategy discussions and document preparations for coordinated Supplementary Protection Certificates for pharmaceutical product in European nations
• Prosecuted and obtained numerous patents, including:
• US 7,820,671 - Peptidomimetic protease inhibitors
• US 7,964,624 - Inhibitors of serine proteases
• US 7,985,762 - Inhibitors of serine proteases
• US 7,985,769 - Compounds and methods for the treatment or prevention of Flavivirus infections
• US 8,003,685 - Thiophene analogues for the treatment or prevention of flavivirus infections
• US 8,039,475 - Co-crystals and pharmaceutical compositions comprising the same
• US 8,158,675 - Compounds and methods for the treatment or prevention of Flavivirus infections
• US 8,252,923 - Peptidomimetic protease inhibitors
• US 8,268,873 - Inhibitors of IMPDH enzyme
• US 8,269,014 - Thiophene analogues for the treatment or prevention of flavivirus infections
• US 8,329,924 - Compounds and methods for the treatment or prevention of Flavivirus infections
• US 8,357,718 - Compounds and methods for the treatment or prevention of Flavivirus infections
• US 8,372,846 - Co-crystals and pharmaceutical compositions comprising the same
• US 8,372,873 - Inhibitors of serine proteases
• US 8,440,706 - Inhibitors of serine proteases
• US 8,800,770 - Packaging for constraining a unit of articles
• US 8,828,466 - Ready-to-eat cereal with reduced sugar coating
• US 8,833,638 - Dual dispensing container
• US 8,919,245 - Induction cooking structure and system and method of using the same
• US 8,944,798 - Gas assisted co-extrusion apparatus and process for forming foods
• US 9,113,657 - Apparatus and method for curled extrudate
• US 9,126,705 - Transportable container for bulk goods and method for forming the same
• US D710,566 - Waffle bar

Prior Experience

• Miller, Canfield, Paddock and Stone, P.L.C., 2007-2008
• Varnum, Riddering, Schmidt & Howlett, 2004-2007

Clerkships

• Federal Public Defender's Office, Law Clerk, 2002-2004

Education

Admissions

Court Admissions

Awards

• Michigan Super Lawyers, Recognized as a Rising Star, 2012-2017

Professional & Community Involvement

American Bar Association

• Section of Intellectual Property Law, Member

• Section of Science & Technology Law, Member

• Food, Cosmetics and Nutraceuticals Committee

State Bar of Michigan

• Intellectual Property Law Section, Member

Kalamazoo County Bar Association

MichBio

Kalamazoo Drop-In Child Care Center

• Board of Directors, 2005-2008

Leadership Kalamazoo, 2007

Domestic Violence Legal Clinic

• Student Attorney, 2002-2005

Press Releases

Alerts

Publications